HC Wainwright Issues Pessimistic Forecast for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective reduced by research analysts at HC Wainwright from $4.00 to $3.50 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 496.66% from the company’s current price. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Adaptimmune Therapeutics currently has an average rating of “Buy” and an average target price of $3.16.

Adaptimmune Therapeutics Price Performance

Shares of Adaptimmune Therapeutics stock opened at $0.59 on Thursday. Adaptimmune Therapeutics has a 12-month low of $0.42 and a 12-month high of $2.05. The stock has a market capitalization of $150.02 million, a P/E ratio of -2.67 and a beta of 2.26. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average price of $0.88 and a two-hundred day moving average price of $1.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Fullcircle Wealth LLC acquired a new stake in Adaptimmune Therapeutics during the third quarter worth about $33,000. Vontobel Holding Ltd. increased its position in shares of Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics in the third quarter valued at $95,000. Boulder Hill Capital Management LP bought a new position in Adaptimmune Therapeutics in the first quarter worth $143,000. Finally, Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.